This report looks at prescribing trends in primary care for antibacterial drugs at SICBL and ICB level with particular focus on prescribing volume of antibacterial agents such as cephalosporins, quinolones, macrolides and tetracyclines. Prescribing data is weighted with STAR-PU prescribing measures, and incorporates C. difficile rates and non-medical prescribing.
If you have any queries about the content of the report please contact us at email@example.com
October 2020 to September 2023
This bulletin provides an update on the current primary care antimicrobial prescribing trends at ICS level in the North of England. It specifically focuses on primary care prescribing, including the top 10 antibacterial drugs prescribed and the variation in the proportion of broad spectrum antibacterials prescribed across the ICSs.
New Drug Evaluations are concise, structured reviews of new drugs recently launched within the NHS. These documents seek to provide a brief overview of the efficacy, safety and cost of new drugs.
Brolucizumab is a monoclonal antibody specific for vascular endothelial growth factor (VEGF). It is indicated for treatment of wet age-related macular degeneration (AMD), and is administered as an intravitreal injection every eight or 12 weeks.
Download the full review below to read more.
NICE has accredited the process used by the Regional Drug and Therapeutics Centre to produce New Drug Evaluations. Accreditation is valid until the 31st of December 2023.
For more information visit www.nice.org/accreditation